Xuanzhu Biopharmaceutical Co.
Latest round
- Series B
Last raised
- Jan 2022
Total raised
- $213M
Investors
- 13
About Xuanzhu Biopharmaceutical Co.
, Ltd. is a new molecular entity and innovative drug developer, focusing on tumors, metabolic diseases, infections and other fields. The company management team is mainly composed of doctors who are engaged in innovative drug design, compound synthesis, early screening and evaluation, preclinical pharmacology and toxicology research, and clinical pharmacology research and have more than 10 years of work experience. In 2018, the company obtained the national class 1 new drug XZP-3621 obtained the phase I-III clinical approval, the national class 1 new drug KBP-5081 obtained the II-III clinical approval, started the phase II clinical trial, and the national class 1 new drug KBP-3571 obtained the II-III phase clinical approval. The company is mainly engaged in the research and development of new molecular entity drugs. The research fields mainly include the field of anti-infection, anti-cardiovascular and metabolic diseases, anti-tumor and other cutting-edge new drug research and development fields. At present, a completely new drug research and development system has been formed, with a professional platform for new drug structure design, evaluation, candidate compound establishment, clinical research, and new drug marketing application. The company self-developed products such as metabolic innovative drug XZP-5610, lung cancer treatment drugs XZP-5809 and XZP-3621, tumor treatment drugs XZP-5955, XZP-P107, XZP-P270 and so on. Revenue is generated through licensing of drug candidates, strategic partnerships, and commercialization of proprietary therapeutics. The company also benefit from milestone payments and royalties from co-development agreements.
Who invested in Xuanzhu Biopharmaceutical Co.
13 investors across 2 rounds
See all investors in Xuanzhu Biopharmaceutical Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Xuanzhu Biopharmaceutical Co.
Who invested in Xuanzhu Biopharmaceutical Co.?
Xuanzhu Biopharmaceutical Co. has 13 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Xuanzhu Biopharmaceutical Co. raised?
Xuanzhu Biopharmaceutical Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Xuanzhu Biopharmaceutical Co. last raise money?
Xuanzhu Biopharmaceutical Co.'s most recent round on record is a Series B, in Jan 2022.
What does Xuanzhu Biopharmaceutical Co. do?
Xuanzhu Biopharmaceutical Co. is a pharmaceuticals company.
Where is Xuanzhu Biopharmaceutical Co. headquartered?
Xuanzhu Biopharmaceutical Co. is headquartered in Beijing, China.
Which VCs invest in companies like Xuanzhu Biopharmaceutical Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Xuanzhu Biopharmaceutical Co.'s stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Xuanzhu Biopharmaceutical Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.